Welcome on Hemarina website
Hemarina is a biotechnology company developing a new generation of oxygen-carrier
for therapeutical and industrial applications
The use of marine hemoglobin as oxygen-carrying RBC substitute was discovered by Pr. François Lallier, Dr. Franck Zal and Pr. André Toulmond.
|
During the last 70 years, attempts have been made to develop an oxygen-carrier which would help cope with the huge deficit of blood worldwide.
Patients undergoing surgery, transplantation, accident victims, soldiers hurt in theatres of operations, victims of terrorist attacks, victims of natural disasters, etc… all await an efficient prodcuct acting as human red blood cells that can complete the lack of blood donation estimated to be over 100 millions of liters per year.
Hemarina has a strong Research and Development activity and develops an oxygen-carrier that has shown promising results in pre-clinical trials for further use in human or for industrial applications where oxygen carrier is needed. Hemarina business model is not to go directly on the ground but to find win-win partnerships with industrials.
This extracellular hemoglobin (Hemarina M-101) is extracted and purified from a marine organism and possesses all the characteristics required for an efficient oxygen-carrier that can be used in broad application spectra.
|
|
|
News
|
|
Franck Zal (CEO) will participate to the Eco & Co program on the French Tebeo chanel Tuesday 12 January 2010 at 7:00 pm. This interview will also be available on the Web during one week.
More...
|
|
HEMARINA was distinguished during the SFT annual meeting, which took place in Nice, Dec. 9th-11th, for the presentation of its new solution HEMO2life® curently under evaluation at the AFSSAPS.
More...
|
|
HEMARINA has received on Nov. 19th 2009 a new award by the Entreprises club of Morlaix county for its innovations.
More...
|
|
HEMARINA has received on Sept. 14th, 2009 at Rennes an award for the most original project since the creation of the enterprise incubator EMERGYS ten year ago.
More...
|
|
HEMARINA has been classified between the most promising start-up in France by Capital magazine in August 2009.
More...
|
|
HEMARINA has been invited by the scientific comity to present its last scientific data during the XII Sympoium on Blood substitute.
More...
|
|
Last publication from Hemarina in collaboration with academic laboratories
Harnois T., Rousselot M., Rogniaux H., Zal F. (2009) High-level production of recombinant Arenicola marina globin chains in Escherichia coli: a new generation of blood substitute. Artif Cells Blood Substit Immobil Biotechnol. 37(3):106-16.
More...
|
Monday, july 21th 2008 was the Hemarina’s premises opening day at the “Pépinière d’Entreprises de Morlaix”...
More...
|
The Chief Technical Officer of Hemarina has received a special mention at the "Prix Bretagne Jeune Chercheur 2007", 5th december 2007...
|
The research and development program of Hemarina, called HEMORGAN was labeled by the competitiveness cluster Mer-Bretagne and received a grant by the ANR...
|
|
Dr. Gilles Avenard Co-Founder and COO of Bioalliance Pharma SA has accepted to be a Board member of HEMARINA.
More...
|
|
